A patient arrives with a phone full of Seoul clinic videos and asks which is better: exosomes, PDRN or PRP. Distributors lead with it too. In the US, it is the second question.
The first is what you can legally obtain and inject. Platelet-rich plasma is autologous — drawn from the patient in front of you, concentrated chairside with a cleared separator, returned to that patient. It is routine in US practice. Exosome products and injectable PDRN or polynucleotide products have no US approval or clearance for any indication. That is not the same thing as off-label use: off-label describes an approved product used outside its labeled indication, and here there is no approved product to be off-label about.
That reorders consent, marketing copy and board exposure before it touches efficacy — one of the sharpest cases of the gap we trace across the wider K-beauty influence on US aesthetic medicine.
Regulatory status, not efficacy, is the first-order difference
PRP gets misdescribed in both directions. FDA does clear the devices that prepare PRP, the separators and concentrating systems reviewed by CBER under “BK” clearance numbers. That clearance covers the separator, not a treatment claim. FDA’s own posted 510(k) summary language for a PRP device says it plainly: “The PRP prepared by this device has not been evaluated for any clinical indications,” and it “is NOT indicated for delivery to the patient’s circulatory system.” There is no FDA-evaluated indication for PRP in skin. What there is instead is a cleared instrument and an autologous material, which is why PRP sits inside ordinary US practice while the other two do not.
Exosome products sit outside it. FDA’s position is unambiguous: “There are currently no FDA-approved exosome products.” Exosomes used to treat conditions in humans are regulated as drugs and biological products under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act, subject to premarket review and approval — an investigational new drug application to study them, a biologics license to market them. They have never been placed in the lighter tissue-product category that lets some cell and tissue products reach market without approval. FDA issued a public safety notification on December 6, 2019 after multiple reports of serious adverse events in Nebraska patients treated with unapproved products marketed as containing exosomes, and enforcement letters calling exosome products unapproved new drugs and unlicensed biologics have continued through at least September 2025. More in our post on whether exosomes are FDA-approved.
Injectable PDRN and polynucleotides share that unapproved posture: searches of FDA’s approved drug labels and its 510(k) database return no match under either polydeoxyribonucleotide or polynucleotide. Elsewhere the picture differs entirely, which is why patients ask: PDRN has been a licensed drug in Italy since 1994 for dystrophic and dystrophic-ulcerative connective tissue disorders; in Korea, PDRN products are pharmaceuticals while polynucleotide injectables are medical devices; in the EU the best-documented polynucleotide injectable is a class III CE-marked device. None of that transfers across the border, and no FDA pathway authorizes personal importation of a non-approved injectable.
What the active material actually is
PRP is the patient’s own plasma concentrated for platelets and the growth factors their granules release. Its strength is provenance: you know what is in the syringe because you drew it. Its weakness is standardization — platelet yield, leukocyte content, activation state and final volume vary with the patient, the system and the operator, which is why the field struggles to compare studies. The same logic separates PRP from PRF, covered in our comparison of PRP and PRF for aesthetic providers.
PDRN and polynucleotides are both purified mixtures of DNA fragments from salmon and trout germ cells — sperm cells yield highly purified DNA with limited risk of impurities. The difference between the two names is molecular weight and the rheology that follows, not two different drugs: a 2025 review proposes a cutoff at 1500 kDa, PDRN below it as the shorter fraction, polynucleotides above it as the longer fraction forming a more porous, viscous three-dimensional structure. The proposed mechanism is adenosine A2A receptor agonism plus nucleotide salvage, with recycled nucleotides supporting production of collagen, elastin and fibronectin. Proposed is the operative word: the work is largely preclinical, and the most-cited pharmacology review carries a corrigendum disclosing that authors hold PDRN patents and that one received manufacturer research support. Background sits on our PDRN reference page, and the topical side of the salmon-DNA story in our article on how salmon sperm microneedling works.
Exosomes are cell-derived extracellular vesicles, and in aesthetic products they are typically allogeneic, from cultured cells of another source. Characterization is the whole problem: vials marketed as exosome products range from purified vesicle preparations to conditioned culture media and cell lysates, and the review literature repeatedly flags inconsistent characterization as a limit on what can be concluded. Our exosomes reference page collects the biology; the clinical article on what professionals should know before injecting exosomes goes deeper on delivery.
How the three compare at a glance
| Attribute | PRP | PDRN / polynucleotides | Exosome products |
|---|---|---|---|
| Source and active material | Patient’s own blood; concentrated platelets | Purified DNA fragments from salmon or trout germ cells | Vesicles from cultured allogeneic cells; often conditioned media or lysates |
| Product class | Autologous, prepared at the point of care | Drug in Italy; pharmaceutical or device in Korea; class III CE device in the EU | Drug and biological product when used to treat a condition |
| US regulatory status | Device cleared; the PRP itself not evaluated for any clinical indication | No approved label, no 510(k); unapproved, not off-label | No approved product for any indication; unapproved, not off-label |
| Strength of human evidence | Nine-RCT meta-analysis: significant but modest | Nine low- and moderate-quality studies; fails to beat active comparators | Small, short, often unblinded trials; low-to-moderate-quality pooled data |
| Typical use case | Skin quality, scarring and hair restoration | Skin quality and periocular skin, where licensed | Adjunct to microneedling or laser for texture, tone and hair density |
| Main limitation | No standardized preparation, no FDA-evaluated indication | Unapproved here; retractions and heavy manufacturer involvement | Unapproved here; inconsistent characterization and documented injection harm |
What the human evidence actually supports
PRP: the most conventional evidence, and still modest
The strongest synthesis for PRP in skin aging is a 2025 meta-analysis of nine RCTs and 358 patients. The benefit is real and small: patient satisfaction risk ratio 1.34 (95% CI 1.07–1.67), objective efficacy risk ratio 1.42 (95% CI 1.01–2.00), adverse events risk ratio 1.21 (95% CI 0.50–2.92), so no safety signal emerged. The authors’ limitations are the honest headline: few and small studies, short follow-up, and no standardized outcome measurement. That is the best-evidenced of the three, which tells you something about the category.
Exosome data in skin is early, small and not independent
The cleanest positive human signal is a 12-week prospective randomized split-face study in 28 patients: an adipose-stem-cell-derived exosome-containing solution with microneedling beat saline with microneedling on Global Aesthetic Improvement Scale scores (p = 0.005), with improvements in wrinkles, elasticity, hydration and pigmentation and no serious adverse events. Twenty-eight patients, one center, 12 weeks, proprietary solution. A 2026 meta-analysis of 39 human studies reported an average 20.2% reduction in facial wrinkles (95% CI 15.3–25.2) and a 23.6% increase in hair density (95% CI 18.1–29.0) — while stating that heterogeneity and nonstandardized protocols limit generalizability. A separate 2026 review of 21 studies, roughly 256 clinical participants, found most showed low-to-moderate methodological rigor and inconsistent exosome characterization. Several trials involve proprietary products and no independent funding statement was located for the split-face study, so none of it is industry-independent. On delivery, see our article on microneedling with exosomes.
Polynucleotides move instrument readings, not blinded global scales
This is the pattern most often left out of a rep’s presentation. The largest synthesis of injectable polynucleotides covers nine studies of low and moderate quality and 219 treated patients, calling outcomes promising for wrinkles, texture and elasticity while noting limited consensus on optimal use. Head to head against an active comparator under blinding, the global scales tend not to separate. A randomized double-blind split-face study of 27 periocular patients found visual analog scale and global aesthetic improvement scores were not significantly different between polynucleotide and hyaluronic acid, though the polynucleotide side improved more on instrument-measured elasticity, hydration, roughness and pore volume. A split-face melasma study of 30 patients found noninsulated microneedle radiofrequency plus polynucleotides no better than the device alone.
Ready to put this into practice?
Explore Empire's hands-on, CME-accredited Functional & Regenerative Medicine courses — live patients, expert faculty, and ongoing mentorship.
There is also a publication-integrity problem. Several of the most-cited polynucleotide and PDRN papers are retracted, including the 72-patient trial long treated as pivotal — whose efficacy outcomes were null anyway — and a 218-patient comparison trial retracted in March 2026 over comparator misidentification. Our explainer on what polynucleotides are and how they are used handles the retractions in full.
Where stem cells fit in this comparison
Providers often assume a fourth column belongs in the table, because marketing blurs exosomes into stem cell therapy. It does not. Briefly: the only stem cell products FDA has approved in the United States are blood-forming hematopoietic progenitor cells from umbilical cord blood — transplant products, not aesthetic ones. Anything injected under a cosmetic or anti-aging stem cell banner is unapproved, and state laws permitting certain unapproved stem cell therapies neither displace federal jurisdiction nor cover cosmetic indications. That comparison has its own literature, so read Empire’s article on how exosomes and stem cells compare on results.
Provenance is a safety issue, not paperwork
The most instructive published harm here is a case report describing a 38-year-old man injected intradermally for acne scars with a lyophilized product marketed as containing human cord-blood conditioned media. By day three he had ulcerated papules and dusky purple discoloration on both cheeks. It resolved by week two into severe atrophic scarring with hyperpigmentation, only modestly improved by three laser sessions. The manufacturer’s own instructions specified topical use only.
In an unapproved category there is no label to rely on and no assurance the vial contains what the carton claims. “It is topical, so it is safe” collapses the moment someone injects it, and the person holding the syringe owns that decision. Nor does combining solve it: an unapproved product added to a cleared device is not an approved treatment. Ask who made the product, what route the manufacturer specifies, and whether your consent form or advertising implies an approval that does not exist.
Frequently asked questions
What is the difference between exosomes and PDRN?
They are unrelated materials. Exosomes are cell-derived extracellular vesicles from cultured allogeneic cells, regulated in the US as drugs and biological products. PDRN is a purified mixture of lower-molecular-weight DNA fragments from salmon or trout germ cells, with a proposed mechanism through adenosine A2A receptor agonism and nucleotide salvage. Neither has a US approval or clearance.
Are exosomes better than PRP?
The comparison has not been made properly. No adequately powered head-to-head trial establishes superiority of exosome products over PRP for a skin indication, and the evidence bases are not comparable: PRP has a meta-analysis of nine randomized trials in 358 patients, while the exosome literature is small, often unblinded studies of poorly characterized products. In US practice the question is moot anyway, since PRP is available and exosome products are unapproved.
Is PDRN the same as salmon DNA?
Substantially, yes — PDRN is purified DNA fragments derived from salmon or trout germ cells, which is where the consumer-facing “salmon DNA” language comes from. The clinically meaningful distinction is molecular weight: PDRN is the shorter fraction and polynucleotides the longer, more viscous one, with a proposed cutoff at 1500 kDa.
Which regenerative treatment has the best evidence?
PRP, by a margin, and it is still modest: nine randomized trials pooled to statistically significant but small benefits on non-standardized outcomes, with no safety signal. Exosome data is early and heterogeneous. Polynucleotide and PDRN data is small-scale, entangled with manufacturer involvement, and marked by repeated failures to beat an active comparator under blinding and by several retractions.
Can these be combined in one treatment?
Combination is common in markets where all three are available, and much of the supportive exosome literature is adjunct data layered onto microneedling or laser. In the US, combining changes nothing legally: an unapproved product added to a cleared device remains unapproved, and stacking two unapproved products compounds the provenance risk.
Where to learn this properly
Choosing among these three is a judgment problem before a technique problem, and technique still has to be taught with hands in tissue. Empire’s Facial Contouring Injectables: Sculptra®, Radiesse®, Exosomes & PDRN Certification Workshop is a hands-on course covering preparation, dilution and injection technique for Sculptra (poly-L-lactic acid) and Radiesse (calcium hydroxylapatite), integration of exosome therapy and PDRN into facial and skin rejuvenation protocols, combination and layering strategies with PDO threads, PRP and PRF, cannula and microcannula technique, the cheeks, jawline, temples, nasolabial folds, chin, neck and décolletage, and complication management and consultation. It is open to MD/DO, DMD/DDS, NP, PA and RN attendees, and it is a non-CME workshop with no credits attached.
If the autologous end of this comparison is where you build first — the defensible answer for most US practices — Empire’s Platelet-Rich Plasma Training is the place to start.
